Presentations & Publications

We are proud of our scientific progress, much of which has been documented via various presentations and publications.

Since 2011, our proprietary platform has enabled the design of three new clinical drug candidates, resulting in four clinical programs. Our scientific progress has been documented in various national and international presentations and publications.

May 2015	Efficacy in collagen induced arthritis models with a selective, reversible covalent Bruton’s Tyrosine Kinase (BTK) inhibitor PRN473 is driven by durable target occupancy rather than extended plasma exposure Bisconte A, Hil RJ, Bradshaw JM, Verner E, Karr D, Finkle D, Brameld KA, Funk JO, Goldstein DM, Nunn PA. Presented at The American Association of Immunologist Annual Meeting, New Orleans, LA, May 8-12, 2015
January 2015	Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694 Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, Johnson AJ, Dubovsky JA. J Biol Chem 2015 Jan 15
November 2014	Irreversible covalent pan-FGFR Inhibitors are highly efficacious against FGFR-dependent cancers. Phan VT, Verner E, Gerritsen M, Bradshaw JM, Goldstein DM, Hill RJ, Karr D, LaStant J, Nunn P, Tam D, Shu J, Funk JO, Brameld KA. Presented at EORTC-NCI-AACR 2014, Barcelona, November 18-21, 2014
November 2014	Development of a Disease Model of Bruton’s Tyrosine Kinase (BTK) Inhibition by PRN473 in Rat Collagen-Induced Arthritis (rCIA) Smith PF, Karr D, Bisconte A, Hill RJ Goldstein DM Nunn PA, Funk JO. Presented at American Conference on Pharmacometrics, Las Vegas, NV October 12-15, 2014
May 2012	Discovery of a highly potent, selective reversible covalent inhibitor of JAK3 kinase [abstract] Hill RJ, Bisconte A, Bradshaw JM, Brameld K, Kim EO, Li X, et al. Arthritis Rheum 2012;64 Suppl 10:2326
April 2012	Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles Serafimova IM, Pufall MA, Krishnan S, Duda K, Cohen MS, Maglathlin RL, McFarland JM, Miller RM, Frödin M, Taunton J. Nat Chem Biol, 2012; Apr 1:8(5):471-6.

Advancing Promising Therapies

See Our Pipeline